RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

RxSight, Inc.NASDAQ: RXST

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 76.1%

Gross margin was 76.1% in Q1 FY2026, up 1.3 pp from a year earlier. On a trailing-twelve-month basis it was 77.0%, up 9.7 pp year over year. Over 3 fiscal years it widened by 33.1 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
76.1%-1.4 pp QoQ
Last fiscal yearDec 2025
76.6%+5.9 pp YoY
LTMMar 2026
77.0%+9.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.3 pp——
1 year+5.9 pp——
3 years+33.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
76.6%
Year-over-year change
+5.9pp

Gross Margin vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's LTM Mar 2026 gross margin of 77.0% is the 4th highest of the 8 companies compared; the peer median is 75.7%.
  • Its year-over-year change of +9.7 pp is the highest of 8, against a peer median of +0.3 pp.
  • Over three fiscal years its change of +33.1 pp compares with a peer median of -0.2 pp.
RXST Competitors Peer median
Gross Margin for RXST and competitors
Company Period LTM level YoY 3-year change
DCTHDelcath Systems, Inc.LTM Mar 202686.0% +1.1 pp+11.4 pp
TMCITreace Medical Concepts, Inc.LTM Mar 202679.7% -0.5 pp-0.8 pp
NPCENeuroPace, Inc.LTM Mar 202678.3% +3.5 pp+5.8 pp
RXSTRxSight, Inc.LTM Mar 202677.0% +9.7 pp+33.1 pp
TCMDTactile Systems Technology, Inc.LTM Mar 202675.7% +1.3 pp+3.9 pp
KIDSOrthoPediatrics Corp.LTM Mar 202673.1% +0.3 pp-1.1 pp
CERSCerus CorporationLTM Mar 202654.3% -1.7 pp-0.2 pp
BFLYButterfly Network, Inc.LTM Mar 202649.2% -11.4 pp-6.9 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
Peer median (excluding RXST) 75.7%+0.3 pp-0.2 pp

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue22.59M49.01M89.08M139.93M134.48M
Cost of Revenue18.08M27.68M35.31M40.98M31.47M
Gross Profit4.52M21.33M53.77M98.94M103.01M
Gross Margin20.0%43.5%60.4%70.7%76.6%
Research & Development24.5M25.98M29.05M34.37M38.55M
Selling, General & Admin32.81M58.67M74.8M101.43M112.65M
Operating Expenses57.3M84.65M103.85M135.8M151.2M
Depreciation & Amortization3.99M4.02M4.24M3.62M0
EBITDA(41.01M)(57.78M)(41.04M)(23.76M)(38.84M)
EBITDA Margin-181.5%-117.9%-46.1%-17.0%-28.9%
Operating Income(52.79M)(63.32M)(50.09M)(36.86M)(48.19M)
Operating Margin-233.6%-129.2%-56.2%-26.3%-35.8%
Interest Income54K1.52M6.57M9.47M2.51M
Interest Expense3.68M4.95M3.31M21K40K
Other Income / Expenses4.11M(3.43M)1.5M9.45M9.31M
Income Before Tax(48.68M)(66.75M)(48.59M)(27.41M)(38.88M)
Pre-Tax Margin-215.5%-136.2%-54.5%-19.6%-28.9%
Income Tax Expense8K9K20K50K66K
Net Income(48.69M)(66.76M)(48.61M)(27.46M)(38.94M)
Net Margin-215.5%-136.2%-54.6%-19.6%-29.0%
EPS (Basic)(1.78)(2.41)(1.41)(0.71)(0.95)
EPS (Diluted)(1.78)(2.41)(1.41)(0.71)(0.95)
Weighted Avg Shares27.37M27.66M34.46M38.87M41.18M
Weighted Avg Shares (Diluted)27.37M27.66M34.46M38.87M41.18M

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.